|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
Salarius Pharmaceuticals, Inc. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
Novavax, Inc. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
Catalyst Biosciences, Inc. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
AEterna Zentaris Inc. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
OrthoPediatrics Corp. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
BioDelivery Sciences International, Inc. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
Biomerica, Inc. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
BioSig Technologies, Inc. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
Tauriga Sciences, Inc. |
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
|
|
Read more ›› |
By: GlobenewsWire - 15 Jan 2021
|
Related companies:
Emerald Bioscience |
|
|
Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly's racial justice efforts Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
Related companies:
Eli Lilly and Company |
|
|
Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
Related companies:
Tris Pharma, Inc. |
|
|
- Ambitious development program for multiple solid tumors with high unmet need, starting with low grade upper tract urothelial cancer (UTUC);- Follows successful clearance of the IND application in Dec 2020 allowing initiation of pivotal Phase 3 clinical trial in patients with low grade UTUC; results... Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
|
|
Bayesian statistical approach based on natural history study could address clinical trial design challenges in centronuclear myopathy Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
|
|
Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
Related companies:
NeuroOne Medical Technologies Corporation |
|
|
- Of the 12 Phase 1b patients evaluable for efficacy as of the ASCO-GI data cut-off date (November 1, 2020), 5 (42%) achieved a partial response (PR) and 8 (67%) have shown a durable response ranging from 6.1 to 13.7 months;- Since the ASCO-GI data cut-off date, 2 additional Phase 1b patients have... Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
Related companies:
Cardiff Oncology, Inc. |
|
|
Expansion comes as City surpasses 100,000 tests per day for three days in a row Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
|
|
Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
Related companies:
BlueWillow Biologics |
|
|
- Focused on Adult Patients that are at Imminent Risk of Suicide;- First Data Readout Expected After Dosing of the Initial 16 Patients Read more ›› |
By: PR Newswire Association LLC. - 15 Jan 2021
|
Related companies:
Seelos Therapeutics, Inc. |
|
|
|